Your doctor needs your trust
Your doctor needs your trust
Most people have heard of the Hippocratic oath, but not many know the prayer of Maimonides by the doctor. He calls on doctors to do everything possible to preserve life and adds something sensible: "Grant my patients to trust me and my art, and follow my instructions and advice."
Trust in the integrity of the doctor is fundamental to the doctor-patient relationship, especially when there are lives at risk. Patients at the Memorial Sloan Kettering Cancer Center, where I am the acting chief physician, depend on us to guide them through their darkest hours, from routine biopsies to experimental clinical trials.
That's why it's so annoying for the thousands of dedicated doctors, nurses, scientists and MSK staff when that trust is called into question. During the last few weeks, questions have been raised about our policies regarding financial relationships with other health care companies and disclosure of those relationships. Now it is essential that we reaffirm our values for our patients and for our entire community.
Photo:
Istock / getty images
Our patients come first. We are committed to providing the best cancer care today and to developing better treatments for the future, which requires that our research be available to the public in the most ethical way possible. We work with companies to develop effective treatments, but we are unshakeable in our commitment to prioritize the needs of patients. To that end, we are conducting a comprehensive review of our disclosure policies, our CEO resigned this month from two external corporate boards and we have instituted a moratorium on the participation of our board members with hospital affiliates.
Modern medicine is changing rapidly. Some experts, including Vivek Wadhwa of Carnegie Mellon, believe that the field will advance more in the next decade than in the last century. Research, driven by changing technology, is responsible.
Research is not something that happens in laboratories to satisfy doctors' curiosity or to answer abstract questions. To be successful, collaboration and trust between patients, doctors and developers is required.
It takes remarkable courage and confidence to volunteer to receive a new treatment. In 1973, the parents entrusted Dr. Richard O'Reilly, of Memorial Sloan Kettering, with his son, who had a severe combined immunodeficiency disorder, the same disease that afflicted the famous "Boy in the Bubble." The parents were willing to work with the doctors in a pioneering procedure. His confidence changed the story: it resulted in the first successful bone marrow transplant from an unrelated donor.
The impulse to market medical research does not have to be in conflict with the patient's care or trust; in fact, it should be rooted in those values. Our doctors and researchers look for new advances to improve and save lives. This approach is patient-centered and is as innovative as modern medicine itself. But the significant cost of medical research, most of which is not covered by federal funds, makes collaboration essential with companies that bring medical advances from the laboratory to the patient. One breakthrough after another has emerged from working with pharmaceutical companies, partnerships with sponsors and the commercialization of intellectual property.
MSK doctors and researchers play an important role in this process, as they help new medications and vaccines to go through the approval process. A study by the New England Journal of Medicine ranked us among the most successful non-profit organizations in the approval of treatments. Over the past 30 years, research at MSK has produced 10 drugs approved by the Food and Drug Administration, including Neupogen, which has transformed the experience of chemotherapy by allowing cancer patients to stay at home and avoid infections that require the constant use of antibiotics. Our research has also revolutionized cancer care through innumerable clinical trials for novel therapies. From personalized medicine to the creation of new standards of care, these trials help treatments reach patients faster.
MSK is not alone. Research institutions across the country are working to bring their own innovative discoveries to the market. Many have robust technology development offices dedicated to this purpose.
When this produces profits, the inventors benefit. But patients earn even more. Profits are reinvested in research, creating a cycle in which today's medical discoveries fund new discoveries in the future.
Offering pioneering treatments to overcome cancer remains a fundamental mission. In the left sleeve of our white coats, the doctors of MSK carry the emblem of an arrow pointing up, towards the future. Three crossbars represent our commitment to patient care, education and research. These guiding principles force us to research new therapies, collaborate with the industry and bring discoveries to market on behalf of the millions of people who urgently need them.
Dr. DeAngelis is the acting chief physician at the Memorial Sloan Kettering Cancer Center.
!function(f,b,e,v,n,t,s)
{if(f.fbq)return;n=f.fbq=function(){n.callMethod?
n.callMethod.apply(n,arguments):n.queue.push(arguments)};
if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version='2.0';
n.queue=[];t=b.createElement(e);t.async=!0;
t.src=v;s=b.getElementsByTagName(e)[0];
s.parentNode.insertBefore(t,s)}(window, document,'script',
'https://connect.facebook.net/en_US/fbevents.js');
fbq('init', '369524843414444');
fbq('track', 'PageView');
.
SOURCE LINK ERESVIRAL.COM https://www.beviral.online
Comentarios
Publicar un comentario